Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is SELLAS Life Sciences Group (SLS) Stock Down -10.64% Today?

Why Is SELLAS Life Sciences Group (SLS) Stock Down -10.64% Today?

Key Takeaways

  • SLS shares were down 10.64% at $16.04 in early trading Thursday, versus Wednesday's close of $17.95, a decline of $1.91.
  • The primary catalyst is a $150 million underwritten offering priced at $13.00 per share — a 27.6% discount to the last close — announced after Wednesday's bell.
  • Secondary pressure comes from profit-taking after Tuesday's 156% surge on positive Phase 3 REGAL survival data for galinpepimut-S.
  • Despite the pullback, the stock remains roughly 115% above Monday's $7.47 close, and the deal was priced 74% above that pre-data level.
  • News Significance Score: 40/100 — a major discounted financing, but a move only about 1.6x the stock's typical daily swing.
  • Traders are watching Friday's expected deal close, the offering price as a de facto floor, and the FDA meeting that precedes a planned 2027 filing.
  • Detailed Price Targets, Earnings history, and Forecast pages are available for readers who want deeper fundamental context on the name.
  • Readers can also explore Trending AI Robots for a live view of the automated strategies currently outperforming.

Opening Summary

SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing cancer immunotherapies, led by galinpepimut-S (GPS), a WT1-targeted vaccine licensed from Memorial Sloan Kettering, and tambiciclib (SLS009), an oral CDK9 inhibitor. Shares traded at $16.04 shortly after Thursday's open, down 10.64% from the prior session's close of $17.95 — a decline of $1.91. The direction is unambiguously lower. The cause is verified and specific: SELLAS priced a $150 million public offering at $13.00 per share late Wednesday, a steep discount to the market price, triggering dilution and re-pricing pressure on a stock that had more than doubled two sessions earlier.

Offering Priced at a Sharp Discount

The company sold 11,538,462 new shares at $13.00 apiece, with gross proceeds expected to reach $150 million before fees; underwriters hold a 30-day option on another 1,730,769 shares that would lift the total to $172.5 million. J.P. Morgan and TD Cowen led the book, with Mizuho and others in the syndicate. The offering is expected to settle Friday, Nov. 20.

The $13.00 clearing level is the crux of Thursday's move. It sits 27.6% below Wednesday's $17.95 close and 32% below Tuesday's $19.15 close. For investors who bought during this week's rally, the deal effectively marked the stock at a level far under their entry, and the new shares add roughly 5.7% to the share count. The raise also comes despite $134.7 million of cash and equivalents on the balance sheet at Sept. 30, which makes it a pre-emptive launch-funding exercise rather than an emergency lifeline — a nuance that limits the selloff but does not remove the dilution overhang.

Profit-Taking After the REGAL Data Surge

Thursday's decline extends a giveback that began Wednesday, when shares fell 6.3%. On Tuesday, SLS rocketed 156% after the Phase 3 REGAL trial of GPS met its primary endpoint in acute myeloid leukemia, showing median overall survival of 24.0 months versus 14.7 months for best available treatment — a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The stock printed an intraday high of $24.89, then faded. A 156% one-day gain creates a deep pool of short-term holders with large gains, and the discounted financing gave them a concrete reason to realize them.

Market Context and Trading Activity

Volume has been extraordinary: roughly 50.3 million shares traded Tuesday and 20.6 million Wednesday, against a typical daily turnover of about 4–7 million shares — several times normal. Early Thursday turnover was far lighter than either session, consistent with a post-deal repricing rather than a fresh wave of institutional selling. This is a company-specific event, not a sector move; the decline is driven by dilution mechanics rather than a shift in biotech risk appetite, and no peer read-through is evident.

On technicals, $13.00 now functions as the reference floor created by the offering, and the stock is trading roughly 23% above it. The $24.89 spike high marks clear near-term resistance, while the pre-data $7.47 close is the deeper support zone.

News Significance Score

The scale runs from 0 — no meaningful news and an ordinary move — to 100, meaning transformative news and an extreme, rare price move. This event scores 40 out of 100. The catalyst is genuinely material: a $150 million raise priced at a 27.6% discount is a major financing for a company of this size, and it mechanically resets the valuation reference. The price response, however, is ordinary by the stock's own standards. At 10.64%, Thursday's decline was only about 1.6 times the average absolute daily move of roughly 6.7%, and moves of equal or greater size occurred 10 times in the last 69 sessions. Strong news combined with a routine swing produces a middling score.

What Comes Next for SLS

The immediate focus is Friday's expected closing of the offering and whether the stock can hold above the $13.00 deal price once the new shares begin trading. Beyond that, the calendar is dominated by the FDA meeting to align on a regulatory path for GPS, with a Biologics License Application targeted for the first half of 2027. Investors also await detailed REGAL results at an upcoming medical conference and Phase 2 tambiciclib data in relapsed or refractory AML at the ASH meeting in mid-December, alongside preliminary first-line AML data expected before year-end. Risks include regulatory timelines slipping, underwriter option exercise adding supply, and the possibility that further capital raises follow as launch preparation costs mount.

Trending AI Robots

Tickeron's Trending AI Robots page highlights the automated strategies performing best in current market conditions. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers are surfaced in this curated section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as conditions change. For readers tracking high-volatility names like this one, it offers a structured way to see which approaches are working right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SLS in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 17, 2026

SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.

SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
13
Web
https://www.sellaslifesciences.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.